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Nearly 40% of patients with advanced NSCLC are in performance status (PS) 2. These 
patients have a shorter life expectancy than PS 0/1 patients and they are 
underrepresented in clinical trials. Data on how platinum-based combination 
chemotherapy affects Health Related Quality of Life (HRQOL) of patients with PS 2 are 
scarce and the treatment of this important group of patients is controversial. 
Methods 
A national multicenter phase III study on platinum based chemotherapy to 432 advanced 
NSCLC patients included 123 patients with PS 2. To explore the treatment impact on 
HRQOL, the development of HRQOL during the first nine weeks were compared between 
PS 2 and PS 0/1 patients. We used the EORTC QLQ-C30 and QLQ-LC13 questionnaires. 
Standardized area under the curve for all HRQOL items, and HRQOL responses 
classified as better, stable or worse, were compared between the groups. 
Results 
Whereas the demographic data at baseline were well balanced between the groups, the 
PS 2 patients had significantly worse function and more severe symptoms than the PS 0/1 
patients. In response to combination chemotherapy, the PS 2 patients had a more 
profound improvement of global QOL, cognitive function, fatigue, dyspnea, sleeping 
problems and appetite loss in comparison to the PS 0/1 group.  
Conclusions 
PS 2 NSCLC patients seem to achieve valuable HRQOL benefits from platinum-based 
combination therapy. Prospective clinical studies with predefined HRQOL outcomes in PS 
2 patients are needed to confirm these findings.   
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INTRODUCTION 
Non-small cell lung cancer (NSCLC) is a common malignancy and a leading cause of 
cancer-death worldwide. The majority of NSCLC patients present with advanced 
disease[16] and palliation and health related quality of life (HRQOL) are thus important 
aspects of their treatment.   
It is estimated that 30-40% of the advanced NSCLC patients present with 
performance status (PS) 2.[17, 24] These patients have shorter life expectancy, and their 
poor PS is suspected to make them more vulnerable to treatment-related side effects.[29] 
PS is also the strongest predictor of survival in patients with advanced NSCLC.[28] 
Despite these important facts, PS 2 patients have been greatly underrepresented in 
clinical trials.  
The importance of HRQOL as an outcome of chemotherapy trials for patients with 
cancer is widely acknowledged. A review of 32 randomized trials examining HRQOL in 
patients with advanced NSCLC undergoing chemotherapy, has confirmed the superiority 
of chemotherapy over best supportive care regarding HRQOL and symptom 
improvement.[9] An Outcomes Working Group[1] within the American Society of Clinical 
Oncology has concluded that, even in the absence of prolonged survival, treatment 
guidelines can be based on improvements of HRQOL alone.  
Investigations on symptomatic improvements and HRQOL benefits as trial 
endpoints are strongly recommended by a European Experts Panel.[12] Furthermore, the 
NICE guidelines on lung cancer[20] call for further research into the effects of 
chemotherapy on HRQOL in patients with advanced NSCLC and PS 2.  
 Bottomley et al[6] reviewed HRQOL methods in 29 randomized controlled NSCLC 
trials.  In general, they found limited details in the reporting of HRQOL results. HRQOL was 
mainly used as a secondary endpoint, and limited space was used for the presentation of 
these data. As a result, the authors suggested separate HRQOL publications in order to 
make adequate explanations and presentations of the findings.   
Platinum-based 2-drug combination chemotherapy is the established first line 
treatment of advanced NSCLC,[25] but remains controversial in the treatment of patients 
with PS 2. Several studies have concluded that combination chemotherapy should not be 
recommended for PS 2 patients.[5, 26, 27, 29] It has been pointed out that combination 
chemotherapy to PS 2 patients may lead to unacceptable toxicity and that this would 




chemotherapy was associated with improved survival when compared to single-agent 
therapy in advanced NSCLC PS 2 patients.[19]  
Limited data are available on how combination chemotherapy affects the HRQOL of 
PS 2 NSCLC patients. In our recent publication,[13] subgroup analysis of some selected 
HRQOL items according to performance status favored patients with PS 2. In this study we 
further explore the impact of combination chemotherapy on HRQOL in PS 2.  
 
 
MATERIAL AND METHODS 
 
Patients 
In our national multicenter phase III study in advanced NSCLC patients, three cycles of 
vinorelbine/carboplatin were compared to three cycles of gemcitabine/carboplatin with no 
significant differences in survival and HRQOL between the two treatment arms.[14] The 
study was designed to detect differences in survival and predefined HRQOL aspects 
between the two treatment arms. Chemonaive patients at all ages with histologically or 
cytologically confirmed NSCLC stage IIIB or IV, adequate bone marrow-, renal- and 
hepatic functions were included.  PS 0-2 were allowed, using the performance status 
scale classified by the Eastern Cooperative Oncology Group.[21] At inclusion, patients 
were stratified according to PS 0/1 vs. PS 2. In the patient population, 123 PS 2 patients 




In both arms, three courses of chemotherapy were given at 3-week cycles. Carboplatin  
Chatelut AUC = 4 (equals Calvert AUC = 5), was administered day 1, and vinorelbine 25 
mg/m2 or gemcitabine 1000 mg/m2 day 1 and 8 in each course. Patients ≥ 75 years 
received 75% of standard doses. Chemotherapy was terminated in case of disease 




Assessment of HRQOL 
We collected patient-assessed HRQOL data using the European Organization for 
Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30[2] 
and the lung cancer specific module QLQ-LC13.[3] The QLQ-C30 is a “core 
questionnaire” which incorporates a range of physical, emotional and social health issues 
relevant to a broad spectrum of cancer patients. Global QOL, physical-, role- , emotional-, 
cognitive- and social function are multi-item scales, as are fatigue, nausea/vomiting and 
pain. Dyspnea, insomnia, appetite loss, constipation and diarrhea are single-item 
measures. 
The lung cancer module is validated for use in lung cancer patients. Pain, 
coughing, sore mouth, dysphagia , peripheral neuropathy, alopecia and hemoptysis are 
measured by single items while dyspnea is a three-item scale addressing dyspnea at rest, 
by walking and by climbing stairs.  
The HRQOL questionnaires completed at baseline, before second and third 
chemotherapy cycle and three weeks after completion of chemotherapy are considered of 
primary interest. Time windows of +/- 10 days from onset of second and third 
chemotherapy courses and +/- 14 days for controls at week 9 were assigned. 
 
Statistical considerations 
All HRQOL items were explored, and these were scored for each patient according to the 
EORTC QLQ-C30 scoring manual.[10] HRQOL-item scores range from 0 to 100. A high 
score in functioning scales represents good function, whereas a high score in symptom 
scales represents more symptoms.  
The mean baseline scores for each HRQOL item were calculated and differences 
between the PS 0/1 and PS 2 patients were tested using the Mann-Whitney U-test.  
Area under the Curve (AUC) of HRQOL scores plotted against time is a summary 
measure of HRQOL.[8] This provides each patient’s longitudinal HRQOL experience as a 
single quantity and was calculated for each item.[11] To adjust for baseline differences, 
the AUC calculation for each patient was based on changes from baseline. Missing data 
were imputed. If data from one assessment point were missing, the mean value of the two 
adjacent ones was used. For patients who withdrew or dropped out before week 9, the 
last value carried forward was used to impute the missing subsequent values. This may 
introduce a bias if the main reason for drop-out was deterioration. To examine this 
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possibility, comparisons were performed with data based on the worse possible score for 
the missing data. Standardized AUC (SAUC) was estimated as AUC divided by time. 
SAUC allows for differences in patient survival and corresponds to calculating the average 
HRQOL. SAUC from baseline to week 9 was compared between PS 0/1 and PS 2 
patients using ANOVA.  
Patients’ responses were also classified as improved, stable or worse for all 
HRQOL items at week 9 according to the NCIC CTG standard QOL analysis 
framework.[22] Symptom or function items were considered worse if the change from 
baseline was > 10 points towards worse without improvement at any time-point after 
baseline. Significant improvement was defined as ≥ 10 points towards bettering in patients 
who did not deteriorate. Patients, who had less than 10-point changes from baseline at 
every HRQOL assessment or failed to meet the criteria for worsening or improvement, 
were considered stable. Distributions of the categories were tested by χ2.  
Due to multiple comparisons, p-values of < 0.01 were considered significant and p 






Patient characteristics according to performance status are given in Table 1. The PS 
groups were well balanced regarding baseline demographic, clinical and histological data. 
Of the 123 PS 2 patients, 61 were treated with vinorelbine/carboplatin and 62 with 
gemcitabine/carboplatin. Five did not complete the baseline QLQ, 4 did not receive any 
chemotherapy and 20 completed only the baseline QLQ. Among PS 0/1 patients the 
corresponding numbers were 10, 2 and 19. This leaves 372 patients for HRQOL analyses, 





Significantly less patients in the PS 2 group received three courses of chemotherapy when 




The compliance rate with respect to completion of the HRQOL questionnaires was 97% in 
both groups at baseline (Figure 1). The overall compliance during the study period was 
91% and 83%, for the PS 0/1 and PS 2 group, respectively. At 3 and 6 weeks, the 
compliance was significantly lower in the PS 2 group (76% vs. 93% and 76% vs. 88%, p < 
0.01).  The rates of completed questionnaires within the time window of +/- 10 days from 
onset of second and third chemotherapy courses were 95% and 94%, respectively and 
89% within +/- 14 days of follow-up at week 9.   
The two PS subpopulations differed significantly at baseline (Figure 2). The PS 2 
patients reported lower function for all the functional scales (p < 0.01). They also had 
significantly more severe symptoms with more fatigue, pain, dyspnea, swallowing 
problems, cough, nausea, insomnia, appetite loss and constipation (symptom scales, p < 
0.01).  
The SAUC based on imputation by carrying the last value forward, is presented in 
Table 3. Results from imputation of worst possible scores were consistent with the 
presented data. Regarding the function scales, a tendency towards improved global QOL 
was achieved among PS 2 patients when compared to the PS 0/1 group. For symptoms, 
PS 2 patients achieved significantly more relief of fatigue, dyspnea, and sleeping 
problems, and they tended towards less pain and appetite loss.  In no items did PS 2 
patients experience significant deterioration when compared to PS 0/1 patients.  
The proportions of patients classified as improved, stable and worse are presented 
in Table 4. More PS 2 patients achieved improvement in global QOL and cognitive 
function and they tended towards more improvement of role function. They also 
experienced more relief of dyspnea measured by QLQ-C30, and tended to a larger 
degree of bettering in fatigue, swallowing problems and appetite when compared to PS 






In the present study of combination chemotherapy, PS2 patients had more improvement 
of global QOL, cognitive function, fatigue, pain, dyspnea, sleeping problems and appetite 
loss than  PS 0/1 patients.   
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The differences in HRQOL gains are not surprising. Taking into account the heavier 
baseline symptom burden of PS 2 patients, they clearly have the greatest potential for 
palliation and HRQOL improvements.  
The HRQOL benefits seen among our PS 2 patients are consistent with previous 
studies. Billingham and Cullen found superior palliation among PS 2 patients in 
comparison to PS 0/1[5] in two randomized trials using mitomycin, ifosfamide and cisplatin 
in the treatment of unresectable NSCLC.[7] These results were based on two randomized 
trials using mitomycin, ifosfamide and cisplatin in the treatment of unresectable NSCLC.[7]  
Furthermore, in a recent randomized phase II study on first line erlotinib versus standard 
chemotherapy of PS 2 advanced NSCLC patients, HRQOL tended to improve rather than 
worsen in both treatment arms.[18] In fact, the authors concluded that unselected 
advanced NSCLC PS 2 patients are best treated with combination chemotherapy in first-
line.   
A major strength of this prospective study is HRQOL analyses based on an 
unselected lung cancer population, largely reflecting the everyday clinical setting. The 
high average age and the large proportion of PS 2 patients reflects the high grade of 
representativity, as nearly 40% of diagnosed advanced NSCLC patients nationally during 
the accrual period were included in this study.  
Missing data in trials involving HRQOL represents, on the other hand, a well known 
and described challenge.[4] Deteriorating patients are likely to have an increased drop-out 
rate in completing HRQOL questionnaires[15], and the lower compliance among PS 2 
patients at weeks 3 and 6 may be a weakness. Another important issue is the chance of 
type I error as false positives may result from multiple testing in post hoc analyses.[31] 
Although a significance level defined at p <0.01 to a certain degree can compensate for 
this,[23] the results of our HRQOL analyses should be interpreted with caution. 
Nevertheless, new HRQOL data on PS 2 patients treated with combination chemotherapy 
are essential and provide valuable information.  
Dyspnea, pain and fatigue are described as the most distressing symptoms in 
advanced NSCLC[30] and consequently these symptoms are of substantial clinical 
interest. In our population, these symptoms were at baseline significantly worse, but 
actually palliated to a larger extent in PS 2 patients when compared to PS 0/1. 
Surprisingly, PS 2 patients did not seem to deteriorate in any of the HRQOL dimensions 
when compared to the PS 0/1 patients.  
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Concerns have been raised that chemotherapy to PS2 patients may further 
deteriorate already compromised HRQOL aspects. Current guidelines have cautioned 
against the use of combination chemotherapy in these patients.[25] The results of the 
present study challenge these conservative therapeutic attitudes towards PS 2 patients. 
We found clinically relevant palliation of traumatic symptoms like fatigue, pain, dyspnea, 
appetite loss, sleeping problems and improved global QOL, role function and cognitive 
function in these patients.  
 In conclusion, combination chemotherapy to motivated PS 2 NSCLC patients 
should not be controversial from a HRQOL perspective. There are no convincing data 
indicating that such treatment deteriorates HRQOL in this patient population. On the 
contrary, clinically meaningful improvements of symptoms and function can be achieved. 
Further prospective studies with predefined HRQOL outcomes in PS 2 patients are 












FIGURE 2.  Mean HRQOL scores at baseline. Panel A: Functioning scales. A high 
function score represents good function. Panel B: Symptom scales.  A high symptom 
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FIGURE 2.  Mean HRQOL scores at baseline. Panel A: Functioning scales. A high 
function score represents good function. Panel B: Symptom scales.  A high symptom 
score represents more symptoms.  * p < 0,01. 
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     n = 309 (72 %) 
       n               % 
PS 2 
   n = 123 (28 %) 




Age, years      
    Median 67 67 
    Range 37 – 86 40 – 84 0.25 
    Age ≥ 75 62 20 25 20 0.52 
Sex      
    Female 120 39 48 39 
    Male 189 61 75 61 
0.97 
Extent of disease      
    St IIIB 87 28 38 31 
    St IV 222 72 85 69 
 
0.57 
Histology      
    Squamous cell 
carcinoma 
79 26 31 25 
    Adenocarcinoma 155 50 54 44 
    Large cell carcinoma 20 7 10 8 









Table 2.  Completion of Chemotherapy according to Performance Status. 
 
PS 0/1   PS 2   Courses n % n % p 
3 264 85 83 68 < 0.01 
2 26 8 12 10    0.39 
1 17 6 24 20 < 0.01 








PS 0/1 PS 2 Outcome 
n SAUC* n SAUC* 
p 
Function      
    Global QOL 276 -1,9 93 2,5 0,049 
    Physical function 278 -5,6 94 -4,4 0,46 
    Role function 278 -8,0 94 -3,5 0,12 
    Emotional function 277 3,1 94 2,7 0,81 
    Social function 277 -5,5 94 -3,9 0,52 
    Cognitive function 277 -1,8 94 0,1 0,29 
      
Symptoms      
    Fatigue 278 5,6 94 -1,3 <0,01 
    Pain C30 278 -1,5 94 -6,7 0,03 
    Chest pain LC13 275 2,0 94 -3,1 0,02 
    Arm/shoulder pain 
LC13 
277 1,2 94 -4,3 0,03 
    Pain elsewhere LC13 274 1,5 91 0,4 0,70 
    Dyspnea  C30 278 0,6 93 -6,7 <0,01 
    Dyspnea  LC13 276 2,2 94 -0,8 0,16 
    Swallowing problems 277 1,3 94 -0,1 0,51 
    Cough 277 -7,3 94 -9,1 0,50 
    Hemoptysis 278 -0,4 94 -1,4 0,42 
    Nausea/vomiting 278 4,2 94 3,2 0,60 
    Insomnia 278 -1,5 94 -9,7 <0,01 
    Sore mouth 277 5,5 93 5,3 0,94 
    Neuropathy 275 3,2 94 5,8 0,22 
    Hair loss 276 6,5 94 6,8 0,89 
    Appetite loss 278 3,9 94 -2,9 0,03 
    Constipation 273 13,0 94 9,9 0,32 
    Diarrhea 278 -1,6 94 -1,0 0,77 
 
 
*SAUC is Area under Curve pr week during the period of interest. A positive SAUC 
indicates improved function or more symptoms. Oppositely, a negative SAUC 
represents worsened function or improvement in symptoms. 
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Improved  Stable  
Worse    n 
PS 2 
% 
Improved   Stable  
Worse 
p 
Function          
    Global QOL 276 32 24 44 93 48 13 39 <0,01 
    Physical function 278 20 26 54 94 27 20 53 0,26 
    Role function 278 26 15 59 94 38 20 42 0,01 
    Emotional function 277 35 40 25 94 37 32 31 0,29 
    Social function 277 31 19 50 94 34 17 49 0,80 
    Cognitive function 277 26 33 41 94 39 18 43 <0,01 
          
Symptoms          
    Fatigue 278 32 11 57 94 48 8 44 0,03 
    Pain C30 278 36 29 35 94 48 20 32 0,09 
    Chest pain LC13 275 20 45 35 94 32 42 26 0,06 
    Arm/shoulder pain 
LC13 
277 21 50 29 94 30 39 31 0,12 
    Pain elsewhere LC13 274 26 39 35 91 32 34 34 0,50 
    Dyspnea C30 278 29 35 36 93 54 20 26 <0,01 
    Dyspnea LC13 276 32 17 51 94 44 13 43 0,10 
    Swallowing problems 277 10 68 22 94 17 54 29 0,04 
    Cough 277 45 37 18 94 45 30 25 0,26 
    Hemoptysis 278 8 81 11 94 10 80 10 0,76 
    Nausea/vomiting 278 19 38 43 94 29 30 41 0,13 
    Insomnia  278 34 37 29 94 43 39 19 0,11 
    Sore mouth 277 9 57 34 93 9 60 31 0,87 
    Neuropathy 275 13 57 30 94 9 52 39 0,20 
    Hair loss 276 6 59 35 94 6 57 37 0,93 
    Appetite loss 278 26 36 38 94 40 26 34 0,02 
    Constipation 273 15 29 56 94 22 29 49 0,23 
    Diarrhea 278 25 53 22 94 20 56 24 0,66 
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